PIC Therapeutics is a biotechnology company focused on transforming the treatment of cancer.
PIC Therapeutics is a biotechnology company focused on transforming the treatment of cancer through the selective modulation of oncogene translation. The company is modulating oncogene translation to dramatically improve cancer patient outcomes. Their precision-based therapeutics target the “master switch” of cancer signaling pathways, selectively blocking oncogene protein production by modulating the Pre-Initiation Complex (PIC) that drives their mRNA translation. Its selective approach has the potential to simultaneously modulate multiple oncogenic drivers leading to a powerful new generation of cancer-treating therapeutics.PIC Therapeutics was founded in 2016 and is headquartered in Natick, Massachusetts, United States.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 19, 2022 | Series A | $35M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Harrington Discovery Institute at University Hospitals | — | Series A |